|
CN104815327A
(zh)
*
|
2005-04-08 |
2015-08-05 |
惠氏有限责任公司 |
多价肺炎球菌多糖-蛋白质缀合物组合物
|
|
US20070184072A1
(en)
|
2005-04-08 |
2007-08-09 |
Wyeth |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
PL2878307T3
(pl)
|
2005-06-27 |
2020-01-31 |
Glaxosmithkline Biologicals S.A. |
Kompozycja immunogenna
|
|
PL3017827T3
(pl)
|
2005-12-22 |
2019-04-30 |
Glaxosmithkline Biologicals Sa |
Szczepionka z koniugatem polisacharydu pneumokokowego
|
|
GB0607088D0
(en)
*
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
US8808707B1
(en)
|
2006-05-08 |
2014-08-19 |
Wyeth Llc |
Pneumococcal dosing regimen
|
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
|
HUE037465T2
(hu)
|
2008-12-18 |
2018-09-28 |
Wyeth Llc |
Eljárás 19A szerotípusú streptococcus pneumoniae poliszacharidok molekulatömegének szabályozására
|
|
KR101307703B1
(ko)
*
|
2008-12-18 |
2013-09-11 |
와이어쓰 엘엘씨 |
탄소를 사용하여 스트렙토코커스 뉴모니에 폴리사카라이드 분자량을 조절하는 방법
|
|
ES2797504T3
(es)
|
2009-03-24 |
2020-12-02 |
Glaxosmithkline Biologicals Sa |
Proteína de enlace del factor H meningocócico utilizada como adyuvante
|
|
BRPI1009829A2
(pt)
|
2009-03-24 |
2016-11-16 |
Novartis Ag |
combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos
|
|
KR101450958B1
(ko)
*
|
2009-04-30 |
2014-10-15 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
폐렴구균 백신 및 그의 용도
|
|
GB201003922D0
(en)
*
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
|
ES2614807T3
(es)
|
2010-06-04 |
2017-06-02 |
Wyeth Llc |
Formulaciones vacunales
|
|
AU2011268507B2
(en)
|
2010-06-25 |
2014-08-14 |
Novartis Ag |
Combinations of meningococcal factor H binding proteins
|
|
US20140112950A1
(en)
|
2011-03-02 |
2014-04-24 |
Manmohan Singh |
Combination vaccines with lower doses of antigen and/or adjuvant
|
|
JP2015505309A
(ja)
|
2011-12-29 |
2015-02-19 |
ノバルティス アーゲー |
髄膜炎菌h因子結合タンパク質のアジュバントされた組み合わせ
|
|
JP2015510872A
(ja)
|
2012-03-07 |
2015-04-13 |
ノバルティス アーゲー |
Streptococcuspneumoniae抗原の増強された製剤
|
|
US20150125486A1
(en)
|
2012-03-08 |
2015-05-07 |
Novartis Ag |
Adjuvanted formulations of pediatric antigens
|
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
RU2015106930A
(ru)
|
2012-09-06 |
2016-10-20 |
Новартис Аг |
Комбинированные вакцины с менингококком серогруппы в и к/д/с
|
|
GB201218660D0
(en)
|
2012-10-17 |
2012-11-28 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
|
KR20140075196A
(ko)
*
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
US20150320852A1
(en)
|
2012-12-18 |
2015-11-12 |
Glaxosmithkline Biologicals Sa |
Conjugates for protecting against diphtheria and/or tetanus
|
|
CA2937190A1
(en)
|
2014-01-21 |
2015-07-30 |
Pfizer Inc. |
Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
|
|
KR20220080201A
(ko)
|
2014-01-21 |
2022-06-14 |
화이자 인코포레이티드 |
접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
|
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
BR112016015835B1
(pt)
|
2014-01-21 |
2023-12-26 |
Pfizer Inc |
Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
|
|
CN103893751B
(zh)
*
|
2014-03-26 |
2016-04-20 |
天津康希诺生物技术有限公司 |
一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
|
|
DK3244917T5
(da)
|
2015-01-15 |
2024-10-14 |
Pfizer |
Immunogene sammensætninger til anvendelse i pneumokokvacciner
|
|
IL255106B2
(en)
|
2015-05-04 |
2023-04-01 |
Pfizer |
Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses
|
|
KR102800419B1
(ko)
|
2015-07-21 |
2025-04-25 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
|
CA3005524C
(en)
|
2015-11-20 |
2023-10-10 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
|
CA3031797A1
(en)
|
2016-08-05 |
2018-02-08 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
KR102437120B1
(ko)
|
2016-08-05 |
2022-08-25 |
사노피 파스퇴르 인코포레이티드 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
KR20190103256A
(ko)
|
2016-12-30 |
2019-09-04 |
수트로박스, 인코포레이티드 |
비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
|
|
US11951165B2
(en)
|
2016-12-30 |
2024-04-09 |
Vaxcyte, Inc. |
Conjugated vaccine carrier proteins
|
|
MX392525B
(es)
|
2017-01-20 |
2025-03-12 |
Pfizer |
Composiciones inmunogenicas para su uso en vacunas neumococicas
|
|
WO2018144439A1
(en)
|
2017-01-31 |
2018-08-09 |
Merck Sharp & Dohme Corp. |
Methods for making polysaccharide-protein conjugates
|
|
BR112019017560A2
(pt)
*
|
2017-02-24 |
2020-04-07 |
Merck Sharp & Dohme |
intensificação da imunogenicidade dos conjugados de polissacarídeo-proteína de streptococcus pneumoniae
|
|
CN111132691A
(zh)
|
2017-06-10 |
2020-05-08 |
创赏有限公司 |
提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗
|
|
US10729763B2
(en)
|
2017-06-10 |
2020-08-04 |
Inventprise, Llc |
Mixtures of polysaccharide-protein pegylated compounds
|
|
US11389540B2
(en)
|
2017-09-07 |
2022-07-19 |
Merck Sharp & Dohme Llc |
Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
|
|
PT3678654T
(pt)
|
2017-09-07 |
2024-08-05 |
Merck Sharp & Dohme Llc |
Polissacáridos pneumocócicos e sua utilização em conjugados imunogénicos de polissacárido-proteína transportadora
|
|
CA3074703A1
(en)
|
2017-09-07 |
2019-03-14 |
Merck Sharp & Dohme Corp. |
Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
|
|
MX2020005779A
(es)
|
2017-12-06 |
2020-10-28 |
Merck Sharp & Dohme |
Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
|
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
|
BR112020014978A2
(pt)
|
2018-02-05 |
2020-12-22 |
Sanofi Pasteur, Inc. |
Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
|
|
US20210009711A1
(en)
*
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2020010016A1
(en)
|
2018-07-04 |
2020-01-09 |
Sutrovax, Inc. |
Self-adjuvanted immunogenic conjugates
|
|
WO2020010000A1
(en)
|
2018-07-04 |
2020-01-09 |
Sutrovax, Inc. |
Improved methods for the preparation of immunogenic conjugates
|
|
AU2019299836B2
(en)
|
2018-07-04 |
2025-08-21 |
Vaxcyte, Inc. |
Improvements in immunogenic conjugates
|
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
WO2020120569A2
(en)
|
2018-12-12 |
2020-06-18 |
Glaxosmithkline Biologicals Sa |
Modified carrier proteins for o-linked glycosylation
|
|
WO2020121159A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
|
KR20240169145A
(ko)
|
2018-12-19 |
2024-12-02 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
|
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
|
EP3757217A1
(en)
|
2019-06-27 |
2020-12-30 |
GlaxoSmithKline Biologicals S.A. |
Methods for protein purification
|
|
MX2022001241A
(es)
|
2019-07-31 |
2022-04-20 |
Sanofi Pasteur Inc |
Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
|
|
EP3777884A1
(en)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
|
JOP20200214A1
(ar)
|
2019-09-03 |
2021-03-03 |
Serum Institute Of India Pvt Ltd |
تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
|
|
US12473379B2
(en)
*
|
2019-09-06 |
2025-11-18 |
Serum Institute Of India Private Limited |
Method for obtaining purified bacterial polysaccharides
|
|
MX2022005252A
(es)
|
2019-11-01 |
2022-06-08 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
|
CA3173729A1
(en)
|
2020-02-23 |
2021-08-26 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
EP3900739A1
(en)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
|
|
EP3919076A1
(en)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
|
|
US20230293657A1
(en)
|
2020-06-25 |
2023-09-21 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
EP4192499A4
(en)
|
2020-08-10 |
2024-09-25 |
Inventprise, Inc. |
Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
|
|
JP2023538736A
(ja)
|
2020-08-26 |
2023-09-11 |
ファイザー・インク |
B群レンサ球菌多糖-タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用
|
|
US12138302B2
(en)
|
2020-10-27 |
2024-11-12 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
TW202227467A
(zh)
|
2020-10-27 |
2022-07-16 |
美商輝瑞大藥廠 |
大腸桿菌組合物及其方法
|
|
EP4240410A1
(en)
|
2020-11-04 |
2023-09-13 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
CA3200968A1
(en)
|
2020-11-10 |
2022-05-19 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
US12357681B2
(en)
|
2020-12-23 |
2025-07-15 |
Pfizer Inc. |
E. coli FimH mutants and uses thereof
|
|
KR102610292B1
(ko)
*
|
2021-02-10 |
2023-12-04 |
에스케이바이오사이언스(주) |
스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
|
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
|
CA3218544A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against bacterial and betacoronavirus infections
|
|
WO2022249107A2
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
JP7714690B2
(ja)
|
2021-05-28 |
2025-07-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
EP4452308A1
(en)
|
2021-12-22 |
2024-10-30 |
GlaxoSmithKline Biologicals S.A. |
Vaccine
|
|
MX2024008039A
(es)
|
2022-01-13 |
2024-07-10 |
Pfizer |
Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y usos de los mismos.
|
|
WO2023192997A2
(en)
*
|
2022-03-31 |
2023-10-05 |
The Children's Medical Center Corporation |
Immunogenic compositions for b-cell recall response to a polysaccharide antigen
|
|
EP4522208A1
(en)
|
2022-05-11 |
2025-03-19 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
|
IL321062A
(en)
|
2022-11-22 |
2025-07-01 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
IL321069A
(en)
|
2022-12-01 |
2025-07-01 |
Pfizer |
Pneumococcal conjugate vaccine preparations
|
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
GB202302579D0
(en)
|
2023-02-23 |
2023-04-12 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
|
AU2024246082A1
(en)
|
2023-03-30 |
2025-10-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
CN121057590A
(zh)
|
2023-04-14 |
2025-12-02 |
辉瑞公司 |
包含缀合荚膜糖抗原的免疫原性组合物及其用途
|
|
WO2024224266A1
(en)
|
2023-04-24 |
2024-10-31 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2024241172A2
(en)
|
2023-05-19 |
2024-11-28 |
Glaxosmithkline Biologicals Sa |
Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
|
|
TW202527906A
(zh)
|
2023-09-14 |
2025-07-16 |
美商輝瑞股份有限公司 |
包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
|
|
WO2025133971A1
(en)
|
2023-12-23 |
2025-06-26 |
Pfizer Inc. |
Improved methods for producing bacterial capsular saccharide glycoconjugates
|
|
AR133640A1
(es)
|
2024-02-14 |
2025-10-22 |
Merck Sharp & Dohme Llc |
Vacunas neumocócicas conjugadas y métodos de uso de las mismas
|
|
WO2025186705A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2025191415A1
(en)
|
2024-03-11 |
2025-09-18 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
|
|
WO2025219904A1
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
|